NCT02640833 - A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor | Biotech Hunter

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 31, 2020

Study Completion Date

February 28, 2021

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNon-Hodgkin Lymphoma

Interventions

DRUG

Duvelisib

Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.

DRUG

Venetoclax

Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.

Trial Locations (10)

Site Reference ID/Investigator# 145674, Baltimore

Site Reference ID/Investigator# 148559, Greenville

Site Reference ID/Investigator# 148561, Goshen

Site Reference ID/Investigator# 148010, Detroit

Site Reference ID/Investigator# 148562, Harvey

Site Reference ID/Investigator# 147922, Chicago

Site Reference ID/Investigator# 147747, St Louis

Site Reference ID/Investigator# 145677, Tucson

Site Reference ID/Investigator# 145145, Boston

Site Reference ID/Investigator# 145146, Lebanon